Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$153.33 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
626.43 million
Earnings per share
-0.152
Dividend per share
N/A
Year To Date Return
-27.94%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Latest News
Broker Notes
Bell Potter says this ASX share could rise 150%+
Share Fallers
Why Aeris Resources, Capricorn Metals, Paradigm, and Silver Mines shares are sinking today
Broker Notes
Why this exciting ASX stock could rocket 90%!
ASX Share Market News
5 things to watch on the ASX 200 on Wednesday
Share Fallers
Why DroneShield, Neuren, Paradigm, and Pilbara Minerals shares are roaring higher today
Healthcare Shares
2 ASX healthcare stocks making huge moves on big news
Healthcare Shares
3 ASX healthcare stocks soaring on positive company updates
Small Cap Shares
Why these small cap ASX shares could deliver very big returns in 2025
Broker Notes
6 ASX All Ords shares lifted to 'strong buy' consensus ratings for the new year
Share Fallers
Why ANZ, Calix, Paradigm, and Platinum shares are tumbling today
Healthcare Shares
Why is this ASX healthcare stock crashing 26% today?
Small Cap Shares
These small cap ASX shares could surge 27% to 38% higher
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
PAR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 18 Sep 2026 | $0.25 | $-0.01 | -4.00% | 3,137,503 | $0.26 | $0.27 | $0.25 |
| 17 Sep 2026 | $0.25 | $0.00 | 0.00% | 1,882,510 | $0.25 | $0.26 | $0.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 29 Jun 2026 | Paul Rennie | Sell | 600,000 | $99,000 |
As advised by the company. Lapse of performance shares
|
| 18 Jun 2026 | Paul Rennie | Buy | 529,410 | $95,293 |
Participation in share purchase plan.
|
| 18 Jun 2026 | Matthew Fry | Buy | 176,470 | $31,764 |
Participation in share purchase plan.
|
| 02 Jun 2026 | Matthew Fry | Buy | 176,470 | $30,000 |
Participation in share purchase plan.
|
| 02 Jun 2026 | Paul Rennie | Buy | 176,470 | $30,000 |
Participation in share purchase plan.
|
| 02 Jun 2026 | Paul Rennie | Transfer | 8,545,848 | $1,324,606 |
Off-market transfer. Assuming off market transfer
|
| 02 Jun 2026 | Paul Rennie | Transfer | 8,545,848 | $1,324,606 |
Off-market transfer. Assuming off market transfer
|
| 02 Jun 2026 | Paul Rennie | Buy | 352,940 | $60,000 |
Participation in share purchase plan.
|
| 19 Feb 2026 | Paul Rennie | Issued | 76,633 | $22,223 |
Issue of options.
|
| 18 Feb 2026 | Matthew Fry | Expiry | 354,958 | $102,937 |
Options expired.
|
| 18 Feb 2026 | Paul Rennie | Expiry | 5,028,423 | $1,458,242 |
Options expired.
|
| 17 Feb 2026 | Paul Rennie | Issued | 1,500,000 | $442,500 |
Issue of securities. 3,200,000 rights
|
| 03 Feb 2026 | Paul Rennie | Exercise | 153,265 | $48,278 |
Exercise of options.
|
| 03 Feb 2026 | Paul Rennie | Buy | 153,265 | $99,622 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Rennie | Executive DirectorManaging DirectorExecutive Chairman | May 2014 |
Mr. Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their Director of business development. He also led the commercialisation of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. He took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. He worked in a number of positions with Mesoblast Ltd. He was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company.
|
| Mr Amos Meltzer | Non-Executive Director | Dec 2020 |
Mr. Meltzer with over 25 years of experience in international trade and in commercialising technologies, life sciences sector. He has presided over life science research and product development projects clinical trials and the commercialisation of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously he served as General Counsel and IP director at two Nasdaq listed companies Compugen and Gilat, as a non executive director of a biotechnology company Evogene and as VP of Business Development and then CEO of an ASX listed biopharmaceutical company Immuron.
|
| Mr Matthew James Fry | Non-Executive Director | Mar 2024 |
Mr. Fry has more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of world class medical diagnostic products. He has experience with global regulatory agencies, in particular the Australian TGA and US FDA. Through his role as Founder and CEO of AM Diagnostics, he drove the company's expansion into the United States in 2009 and is a leading biotechnology device supplier with understanding of sales channels in both the US medical wholesale market and retail market, and how to negotiate with private health providers.
|
| Ms Abby Macnish | Interim Company Secretary | Aug 2022 |
-
|
| Abby Macnish | Interim Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 30,905,712 | 5.16% |
| Citicorp Nominees Pty Limited | 20,339,163 | 3.39% |
| Mr Anthony Mark Van Der Steeg | 17,130,667 | 2.86% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> | 12,674,432 | 2.12% |
| Kzee Pty Ltd <Kzee Superannuation Fund A/C> | 11,887,107 | 1.98% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 10,344,598 | 1.73% |
| Mr Paul John Rennie | 8,322,318 | 1.39% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited <No 1 Account> | 8,322,318 | 1.65% |
| BNP Paribas Noms Pty Ltd | 6,932,047 | 1.16% |
| Obsidian Global Gp Llc | 5,949,080 | 0.99% |
| Mr Terrance Jacob Mitchell | 4,579,647 | 0.76% |
| J P Morgan Nominees Australia Pty Limited | 4,462,130 | 0.74% |
| Mr Adam William Huts | 4,350,932 | 0.73% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 3,565,305 | 0.60% |
| Nancy Edith Wilson-Ghosh <Ghosh Family A/C> | 3,475,835 | 0.58% |
| Capp SMSF Pty Limited <Capp Superannuation Fund A/C> | 3,416,470 | 0.57% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 3,339,717 | 0.56% |
| BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> | 3,221,729 | 0.54% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 3,087,717 | 0.52% |
| Mr Sotera Sueng | 3,000,000 | 0.50% |
